Here are four things to know:
1. The regulations stripped the tax benefits New York-based Pfizer sought from its merger with Allergan, based in Dublin, Ireland.
2. Allergan CEO Brent Saunders said the U.S. government set those regulations to block the deal, valued at $160 billion.
3. To save money in tax revenues, Pfizer recently moved its tax addresses to Dublin. Many political figures such as Hillary Clinton scorned the move.
4. The $160 billion deal is one of the largest deals between drug companies to date.
“For the rules to be changed after the game has started to be played is a bit un-American, but that’s the situation we’re in,” Mr. Saunders said.
More articles on quality & infection control:
Pfizer considers nixing $160B Allergan merger amidst new tax regulations — 3 insights
Time to break the silence — 4 notes on surgeons coping after an adverse event
Zika causes various neurological disorders: 4 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.